{"id":196996,"date":"2026-10-08T17:01:21","date_gmt":"2026-10-08T09:01:21","guid":{"rendered":"https:\/\/www.chinamoneynetwork.com\/?p=168091"},"modified":"2026-10-08T17:01:21","modified_gmt":"2026-10-08T09:01:21","slug":"ribobio-submits-phase-i-clinical-trial-application-for-sirna-drug-rbd3133-targeting-inhbe-to-eu","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2026\/10\/08\/ribobio-submits-phase-i-clinical-trial-application-for-sirna-drug-rbd3133-targeting-inhbe-to-eu\/","title":{"rendered":"Ribobio Submits Phase I Clinical Trial Application for siRNA Drug RBD3133 Targeting INHBE to EU"},"content":{"rendered":"Ribobio Biotechnology Limited (06938.HK) and its subsidiary, Ribocure Pharmaceuticals AB, have successfully submitted an Investigational New Drug (IND) application for...","protected":false},"excerpt":{"rendered":"<p>Ribobio Biotechnology Limited (06938.HK) and its subsidiary, Ribocure Pharmaceuticals AB, have successfully submitted an Investigational New Drug (IND) application for&#8230;<\/p>\n","protected":false},"author":252,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[496,288,194,1215,1542],"tags":[7582,11571,10352,5256,11991,10733,14470,14471,14472,14473,14474,14475],"class_list":["post-196996","post","type-post","status-publish","format-standard","hentry","category-eu","category-medicine","category-news-chinese-law","category-obesity","category-technology","tag-biotech","tag-drug-development","tag-european","tag-healthcare","tag-healthcare-innovation","tag-industry","tag-inhbe","tag-phase-i-clinical-trial","tag-rbd3133","tag-ribobio","tag-ribocure-pharmaceuticals-ab","tag-sirna-drug"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/252"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=196996"}],"version-history":[{"count":1,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196996\/revisions"}],"predecessor-version":[{"id":196997,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/196996\/revisions\/196997"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=196996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=196996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=196996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}